• MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

A multi-stakeholder panel discussion featuring insight on the use of prescription digital therapeutics as tools when managing behavior-driven conditions.

EP. 1: Prescription Digital Therapeutics in Behavior-Driven Conditions EP2

January 6th 2021

Clinicians, a pharmacist, and a payer discuss their current experience with prescription digital therapeutics for behavior-driven conditions and share considerations for expanding on their use in clinical practice.

EP. 2: Integrating Prescription Digital Therapeutics Into Practice

January 6th 2021

Nidal Moukaddam, MD, PhD, Baylor College of Medicine, comments on where she sees prescription digital therapeutics being most useful when managing behavior-driven conditions.

EP. 3: Potential Impact of Prescription Digital Therapeutics

January 6th 2021

Payer and provider insight regarding the potential impact prescription digital therapeutics could have on addressing challenges surrounding the management of behavior-driven conditions.

EP. 4: Prescription Digital Therapeutics: Clinical Outcomes

January 6th 2021

Current experiences noted by various stakeholders in healthcare regarding the impact of prescription digital therapeutics in clinical practice as tools to help manage patients with behavior-driven conditions, and current limitations that need to be addressed to increase their uptake.

EP. 5: Prescription Digital Therapeutics: Increasing Uptake

January 6th 2021

Considerations regarding opportunities to increase payer and provider uptake of prescription digital therapeutics into clinical practice to optimize care for patients with behavior-driven conditions.

EP. 6: Prescription Digital Therapeutics: Coverage and Reimbursement

January 6th 2021

Steven Peskin, MD, MBA, FACP, shares perspective on factors that need to be considered by payers when making decisions about how to cover and reimburse for prescription digital therapeutics used to manage behavior-driven conditions.

EP. 7: Prescription Digital Therapeutics: Unmet Needs

January 6th 2021

Healthcare providers comment on what clinicians would like to see, in terms of data and education, that would help justify the prescribing of digital therapeutics for behavior-driven conditions.

EP. 8: Prescription Digital Therapeutics: Impact of COVID-19

January 6th 2021

Considerations regarding the impact of COVID-19 on managing patients with behavior-driven conditions, and its positive effects on increasing attention around the topic of prescription digital therapeutics.